Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 47% Improvement Relative Risk c19hcq.org Ferreira et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 26,815 patients in Portugal Fewer cases with HCQ (p=0.000054) Ferreira et al., J. Medical Virology, July 9, 2020, doi:10.1002/jmv.26286 Favors HCQ Favors control
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
Ferreira et al., J. Medical Virology, July 9, 2020, doi:10.1002/jmv.26286 (date from earlier preprint)
Ferreira et al., Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection, J. Medical Virology, July 9, 2020, doi:10.1002/jmv.26286 (date from earlier preprint)
Jun 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Chronic treatment with HCQ provides protection against COVID, odds ratio 0.51 (0.37-0.70).
The actual benefit is likely to be larger becasue research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall. Ferri et al. show OR 4.42, p<0.001 [Ferri], which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure.
risk of case, 47.1% lower, RR 0.53, p < 0.001, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ferreira et al., 29 Jun 2020, retrospective, population-based cohort, database analysis, Portugal, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Received: 30 June 2020 | Accepted: 6 July 2020 DOI: 10.1002/jmv.26286 RESEARCH ARTICLE Chronic treatment with hydroxychloroquine and SARS‐CoV‐2 infection António Ferreira MD, PhD1 | António Oliveira‐e‐Silva MD2 | Paulo Bettencourt MD, PhD3 1 Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina, Universidade do Porto, Hospital Rainha Santa Isabel, Centro Hospitalar Universitário de São João, Porto, Portugal 2 Hospital de Braga, Braga, Portugal Abstract Hydroxychloroquine sulfate (HCQ) is being scrutinized for repositioning in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. This antimalarial drug is also chronically used to treat pa- 3 Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina, Universidade do Porto, Hospital CUF, Porto, Portugal Correspondence António Ferreira, MD, PhD, Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina, Universidade do Porto, Hospital Rainha Santa Isabel, Centro Hospitalar Universitário de São João, 4200‐319 Porto, Portugal. Email: aloboferreira@gmail.com tients with autoimmune diseases. By analyzing the Portuguese anonymized data on private and public based medical prescriptions we have identified all cases chronically receiving HCQ for the management of diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases. Additionally, we have detected all laboratory confirmed cases of SARS‐CoV‐2 infection and all laboratory confirmed negative cases in the Portuguese population (mandatorily registered in a centrally managed database). Cross linking the two sets of data has allowed us to compare the proportion of HCQ chronic treatment (at least 2 grams per month) in laboratory confirmed cases of SARS‐CoV‐2 infection with laboratory confirmed negative cases. Out of 26 815 SARS‐CoV‐2 positive patients, 77 (0.29%) were chronically treated with HCQ, while 1215 (0.36%) out of 333 489 negative patients were receiving it chronically (P = .04). After adjustment for age, sex, and chronic treatment with corticosteroids and/or immunosuppressants, the odds ratio of SARS‐CoV‐2 infection for chronic treatment with HCQ has been 0.51 (0.37‐0.70). Our data suggest that chronic treatment with HCQ confer protection against SARS‐CoV‐2 infection. KEYWORDS chemotherapy, disease control, economic reason, public policy, SARS coronavirus, social science, virus classification 1 | INTRODUCTION designed, randomized, double blinded, placebo controlled clinical trials showing any evidence of a therapeutic or preventive effect Several in vitro studies have shown chloroquine phosphate and hydroxychloroquine sulfate (HCQ) to be effective in both pre- of these drugs in SARS‐CoV‐2 infection. These two drugs are also chronically used to treat systemic lupus syndrome erythematosus (SLE), rheumatoid arthritis (RA), and other auto- coronavirus 2 (SARS‐CoV‐2) infection in isolated cells.1‐3 Chlor- immune diseases. SLE patients are at increased risk of viral infec- oquine phosphate and HCQ were also found effective in the tions.8 Increased ratios of serious bacterial and viral infections have treatment of patients with COVID‐19 in small nonrandomized or been shown or are expected in different autoimmune diseases.8‐11 venting and treating severe 4‐6 acute respiratory A recent observational study has Thus, patients with these diseases should be expected to have in- shown no..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit